Th17 cells are a subset of CD4 +
Introduction
Chronic infection with the protozoan parasite Trypanosoma cruzi results in Chagas disease, a Neglected Tropical Disease currently affecting 8-11 million people worldwide and 300,000 people in the United States [1] . Humans usually acquire T. cruzi infection via reduviid insect vectors, but infections also sometimes occur through vertical transmission, the ingestion of contaminated food products, and the receipt of infected biological donations. The disease can cause significant cardiac and gastrointestinal morbidity, but drug therapies are typically noncurative and poorly tolerated [1] . The significant global burden of Chagas disease, coupled with the inefficacy of available treatments, indicates a pressing need to develop novel therapeutics, including preventative and/or therapeutic vaccines to induce protective T. cruzi immunity in at risk individuals. The development of effective vaccines requires a more detailed understanding of the protective host immune responses against T. cruzi infection.
Because T. cruzi promiscuously infects both cells expressing MHC class II and cells expressing only MHC class I, CD8 + T cells are critical for protection against infection of all host targets cells. However, CD4 + T cells also are needed for optimal protection [2] . CD4 + Th1 cells have been shown to provide both systemic and mucosal protection against T. cruzi infection, consistent with the well-established framework of Th1 cells being the CD4 + T cell subset most important against intracellular pathogens [3, 4] . Less is known about the role of other CD4 + T cell subsets during T. cruzi infection.
More recently, studies have found a protective role for IL-17A, the major cytokine produced by CD4 + Th17 cells, raising questions about the possibility of a protective role for Th17 cells [5] [6] [7] . However, multiple subtypes of IL-17-producing cells exist, including αβ T cells, γδ T cells, innate lymphoid cells, and even B cells in T. cruzi infection [8, 9] . In addition, Th17 cells have been shown to be involved in autoimmunity [10] [11] [12] . Thus, it remained unclear from these studies of global IL-17A deficiency whether Th17 cells specifically play a protective or pathologic role in T. cruzi immunity. Although Th17 cells are now known to protect against certain extracellular bacteria and fungi [13] [14] [15] [16] , they are not thought to have a significant function in intracellular immunity.
To investigate the specific effects of different CD4 + T cell subsets in T. cruzi infection, we generated T cell receptor transgenic (TS-CD4-Tg) mice with CD4 + T cell receptors that are specific for p7, an immunodominant epitope encoded by the T. cruzi trans-sialidase, a highly conserved virulence factor and potential vaccine target (S1 and S2 Figs) [17] [18] [19] [20] . Using CD4 + T cells from these mice, we were able to generate parasite-specific Th1 and Th17 cells in vitro. These cells were used for studies in vivo using adoptive transfer experiments, and in vitro using CD8 + T cell activation and macrophage infection assays. Through these experiments, we found that Th17 cells confer robust protection against T. cruzi infection, even surpassing that provided by Th1 cells, through both direct and indirect protective effects.
Results

Th17 cells provide stronger protection from T. cruzi-related mortality than Th1 cells
To study the roles of Th1 cells versus Th17 cells in vivo, in vitro-differentiated TS-CD4-Tg Th1 or Th17 cells were adoptively transferred with naïve polyclonal CD8 + T cells into RAG KO mice, which were then challenged subcutaneously with T. cruzi (S3 Fig, Fig 1A and 1B) . We confirmed the persistence of these transferred cells (S4 Fig + T cells were significantly protected compared to no adoptive transfer. Co-adoptive transfer of Th17 cells led to 100% long-term survival that was significantly higher than survival in all other groups.***p<0.001 by Mantel-Cox log-rank test. (C) T-bet KO Th17 cells resulted in decreases in parasite load comparable to WT Th17 cells when transferred into RAG KO mice (>7/group) with CD8 + T cells. **p<0.01 by two-tailed Student t test. (D) T-bet KO Th17 cells resulted in equivalent long-term protection from mortality compared to WT Th17 cells. Th17 cell cultures also contained undifferentiated cells not expressing the classical Th17 markers RORγt or IL-17 (S3C Fig) , we sought to confirm that the impressive protection was truly a Th17 cell-mediated effect, and not attributable to another cell type present in the Th17 cell cultures. To do so, we used cell purification kits to obtain >90% purity of IL-17 Fig) . Therefore, we asked whether the IFN-γ expressed by a small subset of Th17 cells, or the trans-differentiation of Th17 cells into Th1 cells after transfer, was responsible for the protective effects. To answer this question, we generated T-bet KO TS-CD4-Tg mice lacking T-bet, the transcription factor that drives Th1 differentiation and IFN-γ production (T-bet KO TS-CD4-Tg). Using CD4 + T cells from these mice, we made T.
Because our
cruzi-specific T-bet KO Th17 cells, which are unable to adopt the Th1 phenotype. We gave RAG KO mice T-bet KO TS-CD4-Tg Th17 cells and polyclonal CD8 + T cells, and infected them with T. cruzi. CD4 + T cells recovered from recipient mice 9 and 101 days after infection confirmed that the transferred T-bet KO Th17 cells were veritable Th17 cells, as they did not produce IFN-γ in vivo, but maintained high levels of IL-17A expression (S7A and S7B Fig) .
Mice receiving WT or T-bet KO Th17 cells were similarly protected, with significantly decreased parasite burdens compared to control and 100% long-term survival (Fig 1C and 1D ). The persistence of Th17 cells and their protective effects could be detected more than three months after initial infection (S7C Fig), providing further evidence that a stable Th17 cell response to T. cruzi is possible, and that there is no requirement for Th1 cells or any other IFN-γ + CD4 + T cells for robust T. cruzi immunity.
IL-17A induces NADPH oxidase function to provide direct protection in vitro
To investigate mechanisms of direct protection against T. cruzi infection by Th17 cells, we infected murine peritoneal exudate macrophages (PEM) with T. cruzi trypomastigotes in vitro and added Th1 or Th17 cells for two days. In the absence of T cells, high-level parasite infection occurred. The addition of either Th1 cells or purified IFN-γ alone significantly reduced numbers of cells that became infected after two days. Th1 cells are known to prime macrophage activation for the killing of intracellular microorganisms through the secretion of IFN-γ. Consistent with this, a neutralizing antibody directed against IFN-γ reversed the effects of Th1-mediated protection (Fig 2A-2C ) [24] . The addition of Th17 cells to the cultures also reduced the parasite burden among infected macrophages, indicating that Th17 cells are able to directly protect cells against T. cruzi infection. This effect could be recapitulated by replacing Th17 cells with purified IL-17 cytokine, or abrogated by adding an IL-17A-neutralizing antibody, indicating that the protection is mediated by the IL-17 produced by Th17 cells. Although Th17-derived IL-17A is known to recruit neutrophils and enhance inflammation in extracellular infections, a direct intracellular protective effect has not been previously reported. We confirmed previous studies showing that Th1 cells, through the production of IFN-γ, induce macrophage iNOS to produce nitric oxide [25] , the mechanism underlying the killing of intracellular pathogens. However, NO was not induced by Th17 cells (Fig 2D) , and although the addition of the iNOS inhibitor N6-(1-Iminoethyl)-L-lysine (L-NIL) reversed Th1-mediated protection, it had no effect on Th17-mediated protection (Fig 2E) . These data indicate that the direct protection provided by Th17 cells operates independently of NO generation.
Similar to NO-mediated protection, ROS can also inhibit the growth of intracellular pathogens in neutrophils and macrophages [26] . IL-17A has been reported to induce production of ROS in endothelial cells, but it was unknown whether the cytokine could induce ROS in other cells [27] . We hypothesized that Th17 cells could also induce ROS production in macrophages, and that the induction of ROS was necessary for IL-17-mediated direct protection. To test our hypothesis, we infected bone marrow-derived macrophages (BMDMs) generated from WT and gp91 phox KO mice. The latter are genetically deficient in a critical subunit of the NADPH oxidase, resulting in a defective phagocyte respiratory burst response. Following infection of these cells, we treated them with IFN-γ or IL-17A for 48 hours. The gp91 phox deficiency did not affect the induction of NO (Fig 2F) . In both infected WT and gp91 phox KO BMDM, IFN-γ treatment induced NO production, but IL-17A did not (Fig 2F) . In WT BMDM, both IFN-γ and IL-17A protected against infection and intracellular growth of T. cruzi. Deficiency of the gp91 phox subunit of NADPH oxidase had no effect on IFN-γ-mediated protection, but reversed IL-17A-mediated protection, indicating that functional NADPH oxidase is required for this mechanism, and suggesting the involvement of ROS generated during the respiratory burst (Fig 2G) .
IL-17A does not mediate protection by Th17 cells in vivo
Given our findings concerning IL-17-mediated protection in vitro, we asked whether IL-17A was also responsible for the protection observed in vivo. We first neutralized IL-17A in RAG KO mice reconstituted with Th17 cells and polyclonal CD8 + T cells by injection of a monoclonal anti-IL-17A antibody previously shown to reverse IL-17A function in vivo [28, 29] . Neutralizing IL-17A had no effect on parasitemia levels or survival percentages in these mice (Fig 3A  and 3B ). We also overexpressed IL-17A in RAG KO mice receiving polyclonal CD8 + T cells alone using a recombinant IL-17A-producing adenovirus (IL-17A AdV). Although mice injected with IL-17A AdV had markedly higher serum levels of IL-17A (28 ng/ml ± 16 in IL-17 AdV sera versus <0.02ng/ml in control AdV sera), overexpression of IL-17A alone was not enough to replace Th17 cells, and did not protect mice also receiving CD8 + T cells (Fig 3C and   3D ). Overall, these results indicate that IL-17 is dispensable for the major in vivo protective effects induced by Th17 cells, despite being the major Th17 cytokine implicated in previous reports on Th17-based protection and pathology. Therefore, in T. cruzi infection, Th17 cells must function through an IL-17-independent mechanism to protect.
Helper effects on CD8 + T cells execute Th17-mediated protection in vivo
To discriminate between direct protective versus indirect T helper effects, we studied protection provided by Th17 cells transferred alone or with polyclonal CD8 + T cells. CD8 + T cells were needed for optimal Th17-mediated protection ( Fig 4A and 4B ), indicating Th17 helper effects for CD8 + T cells were most important in vivo. However, the mechanism of Th17 helper effects on CD8 + T cells could be due to Th17 cells directly instructing these cells, or Th17 cells indirectly affecting these cells via the activation of antigen-presenting cells. To distinguish between these potential mechanisms, naïve polyclonal CD8 + T cells were stimulated with suboptimal α-CD3 in vitro. Th17 cells and/or immature dendritic cells (DCs) were added to these cultures to provide potential co-stimulatory help. In the absence of Th17 cells, CD8 + T cells exhibited progressive degrees of proliferation with sub-optimal α-CD3 stimulation and increasing doses of DC (Fig 4C) , as detected by dilution of the cell staining dye CFSE. However, nearly 100% of CD8 + T cells proliferated maximally when Th17 cells were introduced, even in the absence of DC. These data indicate that Th17 cells directly and strongly enhance the activation of naïve CD8 + T cells.
Th17 cells exert T helper effects on CD8 + T cells via IL-21
In addition to increasing the proliferation of CD8 + T cells, Th17 cells also induced these cells to increase the expression of surface CD44 (a marker of activated T cells), the effector cytokine IFN-γ, and the chemokine MIP-1α, indicating an activated state of CD8 + T cells (Fig 4D) .
These helper effects on CD8 + T cells were also detectable using supernatants (SN) from activated Th17 cells, implicating soluble factors ( Fig 4D) . However, consistent with our previous in vivo results, neutralization of IL-17A did not prevent the Th17-mediated activation of CD8 + T cells in vitro ( Fig 4D) . By co-culturing sub-optimally stimulated CD8 + T cells with individual purified Th17 cytokines, we discovered that IL-21 alone recapitulated this potent help, inducing a state of CD8 + T cell activation similar to that seen with the addition of Th17 cells or Th17 cell SNs ( Fig 4E) . We confirmed that our Th17 cells produced significant amounts of IL-21, while the Th1 cells did not ( Fig 4F, S3F Fig) .
In vitro assays demonstrated that IL-21R KO CD8 + T cells are unable to be activated by increased in mice receiving IL-21R KO CD8 + T cells ( Fig 5C) . As a result of this failed protection, all mice receiving IL-21R KO CD8 + T cells succumbed to infection while 100% of mice receiving WT CD8 + T cells with Th17 cells survived long-term ( Fig 5D) . These studies clearly demonstrate that Th17-mediated protection in vivo operates through the secretion of IL-21, and the resulting indirect T helper effects on CD8 + T cells.
Th17 cells result in greater numbers of CD8 + T cells, higher levels of Tbet expression and stronger antigen-specific responses than Th1 cells addition, CD8 + T cells primed by Th17 cells either in vivo (Fig 6B) or in vitro (Fig 6C) expressed higher levels of T-bet compared with Th1-primed cells, which has been associated with higher cytotoxic activity and IFN-γ production [30, 31] . IFN-γ ELISPOT and ICS assays comparing spleen cells recovered from Th1-or Th17-transferred mice demonstrated that mice receiving Th17 cells also had >6-fold stronger total spleen cell responses to T. cruzi TS antigen, and >10,000-fold greater frequencies of antigen-specific CD8 + T cells than mice receiving Th1 cells (Fig 6D and 6E) . Overall, these results indicate that both quantitative and qualitative differences distinguish Th1-and Th17-induced CD8 + T cells. (Fig 7C and 7D) . vivo by vaccination when the appropriate biasing adjuvants for promoting Th17 cell responses are used.
Discussion
Recent studies demonstrating that IL-17 confers resistance against T. cruzi infection raised the possibility that Th17 cells could play a protective role, although Th1 cells are typically considered the most important CD4 + T cell subset for immunity against T. cruzi as well as other intracellular organisms. Th17 cells are known to be important for protection against a number of extracellular bacteria and fungi [13, 33, 34] , but are not believed to function significantly against intracellular pathogens. In addition to the protective roles of Th17 cells in the human immune system, Th17 cells are also known to drive pathology in many autoimmune and inflammatory diseases, including multiple sclerosis and rheumatoid arthritis [8] . Mechanistically, we discovered that through the secretion of IL-17A, Th17 cells trigger the function of NADPH oxidase to provide direct protection to infected cells. A previous report suggests that IL-17A may function to retain T. cruzi within the endosomes of host cells [35] . Our discovery that IL-17A acts through NADPH oxidase, involved in the phagocyte respiratory burst, indicates that this cytokine may direct synergistic mechanisms to promote immunity in infected macrophages. NADPH oxidase functions in the cell to produce superoxide and other ROS; these reactive products could protect against T. cruzi by directly killing intracellular pathogens or by functioning as signaling molecules to activate other protective pathways. Future investigations should focus on elucidating the detailed mechanisms of protection and the signaling events involved in IL-17 receptor triggering of NADPH oxidase activity.
In addition, we demonstrated that the major mechanism of protection provided by Th17 cells in vivo is the help provided to critical CD8 + T cells, the major effector cells responsible for 
Materials and Methods
Ethics statement
All animal studies were conducted in accordance with the "Guide for the Care and Use of Laboratory Animals" manual published by the National Research Council and endorsed by the Assessment and Accreditation of Laboratory Animal Care (AAALAC), with the approval of the Institutional Animal Care and Use Committee (IACUC)/Animal Care Committee (ACC), under protocol #1106, assigned by Saint Louis University's IACUC. All mice were maintained in an AAALAC accredited facility at Saint Louis University.
Mice
BALB/c mice (NCI Charles River Laboratories, Frederick, MD), RAG KO mice (The Jackson Laboratory, Bar Harbor, ME), and T. cruzi trans-sialidase amino acids 57-74 (TSaa57-74)-specific TCR transgenic mice on the Thy1.1 BALB/c background (TS-CD4-Tg, generated in the Hoft laboratory) were used throughout this study. Tbx21-/-mice (The Jackson Laboratory, Bar Harbor, ME) and IL-21R KO BALB/c mice (provided by Dr. Manfred Kopf, ETH Zurich) were used to generate CD4 + and CD8 + T cells for adoptive transfer experiments. C57BL/6 wild type mice (WT, NCI Charles River Laboratories, Frederick, MD) and B6.129S6-Cybb tm1Din /J mice lacking the gp91 phox catalytic subunit of NADPH oxidase (gp91 phox KO, The Jackson Laboratory, Bar Harbor, ME) were used to generate bone marrow-derived macrophages. Mice were housed under specific pathogen free conditions. Sample sizes were based on previous experience, and sample size calculations were approved by the Saint Louis University Animal Care Committee and follow AAALAC guidelines and recommendations. All studies included ageand gender-matched groups. Although no formal blinding was done, all key experimental results were reproducible in multiple experiments and when conducted by different individuals in the laboratory.
Parasites and challenges
The Tulahuèn strain of T. cruzi was passaged through BALB/c mice and Dipetalogaster maximus insects. Blood form trypomastigotes (BFT) were collected from infected mice and used for systemic challenges in BALB/c mice. Culture-derived metacyclic tryptomastigotes (CMT) were generated as described [38] and used for in vitro studies and for the systemic challenges of RAG KO BALB/c mice. Systemic challenges were performed by subcutaneous (s.c.) injection of 5,000 BFTs or CMTs re-suspended in in 100 μl phosphate buffered saline (PBS). In vitro infections of macrophages were performed by culturing cells with CMT at 5-10 multiplicities of infection (MOI).
Murine vaccinations
We used a DNA vaccine encoding the consensus TS enzymatic domain as described previously [19] , originally provided by Dr. Maurício M. Rodrigues (São Paulo, Brazil). BALB/c mice were immunized with 100 μg TS-DNA or control DNA intramuscularly (i.m.). We also vaccinated mice intranasally (i.n.) with 50 μg recombinant trans-sialidase plus 10 μg CpG-containing oligodeoxynucleotides (ODN) 1826 (Invivogen, San Diego, CA). For dendritic cell (DC) vaccines, splenic DC were isolated after intraperitoneal (i.p.) injection of BALB/c mice with 5x10 6 B16 cells expressing Flt-3 ligand as previously described [39] . DC were induced to mature in vivo with 2 μg lipopolysaccharide given intravenously (i.v.) and harvested from spleens 16 hours later using α-CD11c microbeads (Miltenyi Biotec, Inc., Auburn, CA). The purity and activation status of DC were determined by staining for CD11c, CD86 and MHC class II, and >90% pure CD11c + DC were obtained. DC were pulsed with 100 μg/ml TS peptides p7 (TSaa57-74, aa sequence KVTERWHSFRLPALVNV) and/or 100 μg/ml TSKd1 (TSaa359-367, aa sequence IYNVGQVSI) for 90 minutes at 37°C, washed and then injected i.v. into BALB/c mice (1x10 
Production of TS-specific CD4 + T cell clones
We screened various 18mer peptide sequences from the consensus catalytic region of TS using IFN-ɣ ELIPSOT assays and identified an immunodominant I-A d -restricted CD4 + T cell epitope (p7, TSaa57-74, aa sequence KVTERWHSFRLPALVNV, S1 Fig, S1 Table) . We prepared T cell clones as described previously [2] . Briefly, we immunized mice with TS DNA 3 times, each 2 weeks apart. Two weeks after the third immunization, spleen cells were harvested and CD4 + T cells purified with α-CD4 microbeads (Miltenyi Biotec, Auburn, CA). T cells were stimulated in vitro with recombinant TS protein or irradiated spleen cells pulsed with TSaa57-74 (p7) in the presence of 10 U/ml IL-2. After 2 cycles of antigen stimulation and IL-2 expansion, T cell cloning was performed by limiting dilution.
Generation of TS-CD4-Tg mice
We amplified clonal TCR-α and TCR-β chain cDNA from a TS p7-reactive T cell clone. We then subcloned these TCR-α (Vα2) and TCR-β (Vβ8. 
Generation of Th1 and Th17 cells
Trans-sialidase-specific T cell lines were derived from naïve TS-CD4-Tg mice. Spleens from naïve Thy1.1 + transgenic mice were harvested, and CD4 + T cells were purified by positive selection using α-CD4 microbeads (Miltenyi Biotec, Auburn, CA). The CD4 + T cells were stimulated with either α-CD3/α-CD28-coated plates or with irradiated CD4 + and CD8 + depleted Thy1.2 + BALB/c splenocytes pulsed with TSaa57-74 (p7) at 2.5 μg/ml. Th1 biasing conditions included 10 ng/ml recombinant mouse IL-12 (Genetics Institute, Cambridge, MA) and 10 μg/ ml anti-IL-4 neutralizing mAb 11B11 (NCI Biological Resources Branch, Frederick, MD). Th17 biasing conditions included 1 ng/ml recombinant human TGF-β (Biolegend, San Diego, CA), 50 ng/ml recombinant mouse IL-6 (Invitrogen, Carlsbad, CA), 20 ng/ml recombinant mouse IL-23 (R&D Systems, Minneapolis, MN), 10 μg/ml anti-IL-4 (NCI Biological Resources Branch), and 10 μg/ml anti-IFN-γ neutralizing mAb XMG1.2 (BD Pharmingen, San Diego, CA). Every 3 days, Th1 cell cultures received 10 U/ml IL-2 while Th17 cell cultures received 20 ng/ml IL-23. Cells were stimulated again 1 week later in the presence of the same biasing cytokines and antibodies. IL-2 or IL-23 was again added 3 days after the second stimulation. Th1 and Th17 cells were used one week after the second stimulation. Polyclonal Th17 cells were generated similarly using wild-type CD4 + T cells; on days 0 and 7, these cells were stimulated with immature DCs pulsed with the supernatants of repeatedly freeze-thawed T. cruzi trypomastigotes. IL-17 + cell purification was performed using Miltenyi IL-17 cell secretion purification kits according to manufacturer instructions.
Adoptive transfers and assessment of protective immunity
In vitro generated Th1 or Th17 cells were transferred i.v. into RAG KO mice, along with polyclonal CD8 + T cells purified from naïve BALB/c mice by positive selection using α-CD8 microbeads (Miltenyi Biotec, Auburn, CA). RAG KO mice received 0.5-2 x 10 6 Th1 or Th17 cells, and 3-5 x 10 6 CD8 T cells, by tail vein injection and were challenged s.c. one day later with 5,000 CMT. Parasitemia was measured post-infection microscopically using 1.5 μl peripheral blood taken from the tip of the tail. Protection was also assessed by survival of infected mice. At 3, 6, 7 and 10 days post-infection, the spleens from representative mice were harvested for immune studies.
In vivo IL-17A neutralization CD8 + T cells were transferred along with TS-CD4-Tg Th17 cells into RAG KO mice that were infected s.c. the following day with 5,000 T. cruzi CMT. In order to neutralize IL-17A, mice were injected intraperitoneally (i.p.) with 100 μg of either anti-mouse IL-17A mAb (clone 17F3) or mouse IgG1 isotype control (clone MOPC-21), both from Bio X Cell (West Lebanon, NH). Mice were injected with antibodies every 48 hours, beginning 1 day before infection and continuing for 30 days post infection.
IL-17A adenovirus
A recombinant adenovirus expressing murine IL-17A was originally described by Schwarzenberger et al. [41] and generously provided by Dr. Shabaana Khader (Washington University, Saint Louis, MO). A control recombinant adenovirus (Ad5) expressing β-galactosidase (β-gal) was also used [42, 43] . Viruses were propagated in HEK-293A cells at Saint Louis University using endotoxin-free conditions, purified by CsCl as previously described [44] , and stored at -80°C in 20mM Tris (pH 8) with 4% sucrose. RAG KO mice were injected i.v. with 5x10 9 PFU of recombinant adenovirus encoding either mIL-17A (IL-17A AdV) or β-gal (ctrl AdV) one day prior to infection and 7 days post-infection. Mice also received CD8 + T cells i.v. and were challenged s.c. with 5,000 T. cruzi CMT. IL-17A was measured in the serum of infected mice by ELISA according to the manufacturer's instructions (BioLegend, San Diego, CA).
Flow cytometry and intracellular cytokine staining
Cell surface staining was performed according to standard procedures using antibodies against murine CD3, CD8, CD4, CD19, CD44 and Thy1.1 (CD90.1), all purchased from BD Pharmingen (San Diego, CA). For intracellular staining, monoclonal antibodies against IFN-γ (BD Pharmingen), IL-17A, IL-17F, MIP-1α, RORγt and T-bet (eBioscience, San Diego, CA) were used. For intracellular staining of in vitro cultures, cells were restimulated with phorbol-12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (500 ng/ml) for 3 hours. For intracellular staining of spleen cells post-infection, cells were restimulated ex vivo with A20-TS for 6 hours. All intracellular stained cells were cultured with monensin (GolgiPlug, 1 μl/ml) and brefeldin A (GolgiStop, 0.67 μl/ml) for the last 3 hours of stimulation at 37°C (both from BD Pharmingen). After surface staining, cells were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (eBioscience) before intracellular staining, according to manufacturer's instructions. Cells were analyzed with a BD LSR II flow cytometer and FlowJo v7 software (Tree Star, Inc.).
In vitro protection assays
To generate peritoneal exudate macrophages (PEM), BALB/c mice were injected i.p. with 100 μg Concanavalin A (Sigma Aldrich, Saint Louis, MO). Four days later, PEM were harvested from the peritoneal cavity of these mice and plated in 8-well tissue culture slide chambers (Nunc LabTek from Thermo Scientific, Waltham, MA) at 1.25x10 6 cells/well in DMEM with 10% FBS. After 2-5 hours, nonadherent cells were washed away and PEM were infected with T. cruzi CMT at an MOI of 5 (6.25x10 6 parasites/well) for 3 hours. Extracellular parasites were then washed away and TS-CD4-Tg Th1 or Th17 cells added at a macrophage to T cell ratio of 25:1 (5x10 4 cells/well). Two days later, slide chambers were removed from slides, and slides were washed, dried, fixed and stained with a modified Wright Giemsa stain, Diff-Quik (IMEB, Inc., San Marcos, CA). The number of infected macrophages was determined microscopically.
Variations of this assay included using neutralizing antibodies against IFN-γ (clone XMG1.2, BD Pharmingen) or IL-17A (clone TC11-18H10, BD Pharmingen) at 10 μg/ml, using the purified cytokines mIFN-γ (1000 U/ml, Genentech, San Francisco, CA) or recombinant mouse IL-17A (100 ng/ml, R&D Systems) instead of T cells, and inhibiting inducible nitric oxide synthase (iNOS) with N6-(1-Iminoethyl)-L-lysine (L-NIL, 1mM, Sigma Aldrich, Saint Louis, MO). Supernatants from the infected macrophage cultures were collected 24 and 48 hours post infection. Nitric oxide concentration was estimated by measuring nitrite concentration in supernatants with the Griess reagent system according to the manufacturer's instructions (Promega, Fitchburg, WI). For experiments with bone marrow-derived macrophages (BMDM), bone marrow was harvested from the femurs and tibiae from C57BL/6 WT OR C57BL/6 gp91 phox KO mice. Cells were cultured on 96-well and 6-well plates with 20 ng/ml recombinant mouse M-CSF (PeproTech, Rocky Hill, NJ) in DMEM with 10% FBS for 7 days. BMDM were then removed from culture plates with CellStripper non-enzymatic dissociation reagent (Corning, Corning, NY), transferred to 8-well slide chambers at 2x10 5 cells/well, and infected with CMT at MOI of 10.
Three hours post infection, extracellular parasites were washed away and either IFN-γ or IL-17A was added. Two days later, slides were washed, dried, fixed and stained as described above. 
CD8
T. cruzi TS-specific IgG serum ELISA
Nunc Maxisorp flat-bottom 96-well plates (eBioscience) were coated with 5 μg/ml of recombinant trans-sialidase protein at 4°C overnight. Plates were washed with PBS-T and blocked with 10% FBS at room temperature, then mouse serum samples serially diluted in PBS were added to wells and incubated overnight. Plates were washed and incubated with an anti-mouse IgG antibody conjugated to horse radish peroxidase to detect TS-specific antibodies. Plates were developed with TMB substrate, and the reaction was stopped with H 2 SO 4. Plates were analyzed at 450 nm with a reference of 540 nm, and endpoint titers were determined as OD readings above the highest OD measured for uninfected controls.
Statistics
Statistical analyses were performed using Prism v4 software (GraphPad Software, Inc., La Jolla, CA). Mann-Whitney U tests or unpaired Student t tests were used to compare responses between groups. Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests were used to compare survival between groups. All data are presented with standard errors, ranges or scatter plots to allow easy assessment of the variation. 
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